David Bonita resigned as a class II independent director of Loxo Oncology Inc., effective Dec. 22.
Bonita's resignation is not the result of any disagreement with the company on any matter relating to its operations, policies or practices.
Loxo Oncology director resigns
Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion
Global M&A by the Numbers: Q2 2022
Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms
Infographic 2022 Top Tech Trends Shaping Corporations
David Bonita resigned as a class II independent director of Loxo Oncology Inc., effective Dec. 22.
Bonita's resignation is not the result of any disagreement with the company on any matter relating to its operations, policies or practices.